Scenarios that move TEVA
Teva Pharmaceutical Industries Limited Ordinary Shares
Scenarios that move TEVA: 30 analyses, 15 positive, 15 negative.
- · ◇ What if… Benjamin Netanyahu leaves Israel's premiership before 2027 — ▲ · impact +45 · confidence high · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▼ · impact -5 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -34 · confidence medium · horizon immediate
- · Viatris to acquire Pacira for $1.65B in pain portfolio deal — ▼ · impact -21 · confidence medium · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +26 · confidence low · horizon quarters
- · Pacira BioSciences shares skyrocket in today's trading — ▼ · impact -27 · confidence medium · horizon quarters
- · ◇ What if… Plague outbreak in Russia continues and spreads further — ▲ · impact +18 · confidence low · horizon weeks
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -8 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▼ · impact -18 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▼ · impact -30 · confidence low · horizon weeks
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +20 · confidence low · horizon quarters
- · uniQure plunges after additional Huntington's disease study data — ▲ · impact +26 · confidence medium · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▼ · impact -8 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +12 · confidence low · horizon quarters
- · ◇ What if… Gadi Eizenkot becomes Israel's next prime minister — ▲ · impact +44 · confidence high · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▼ · impact -9 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +25 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +20 · confidence low · horizon quarters
- · ◇ What if… Naftali Bennett becomes Israel's next prime minister — ▲ · impact +28 · confidence low · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -8 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +10 · confidence low · horizon quarters
- · Xenon files epilepsy NDA as depression study setback weighs — ▼ · impact -8 · confidence low · horizon quarters
- · ◇ What if… Israel strikes four countries in 2026 — ▼ · impact -52 · confidence low · horizon weeks
- · Definium reports second Phase III success in anxiety program — ▼ · impact -16 · confidence medium · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +10 · confidence low · horizon quarters
- · ◇ What if… Benjamin Netanyahu becomes Israel's next prime minister — ▼ · impact -29 · confidence medium · horizon weeks
- · ◇ What if… Israeli forces withdraw beyond the Litani River by December 31 — ▲ · impact +26 · confidence medium · horizon weeks
- · ◇ What if… Netanyahu leaves office as Israel's prime minister by end of 2026 — ▲ · impact +45 · confidence high · horizon quarters
- · ◇ What if… Israel closes its airspace by September 30 — ▼ · impact -45 · confidence low · horizon weeks
- · ◇ What if… Israel-Iran ceasefire continues through September 30 — ▲ · impact +45 · confidence low · horizon quarters